

March 14, 2017



## **Cantabio Pharmaceuticals to Present at the 2nd Annual Neuroscience BioPartnering and Investment Forum at the New York Academy of Sciences in New York**

SAN FRANCISCO, CA -- (Marketwired) -- 03/14/17 -- Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer's, Parkinson's and other related neurodegenerative diseases, today announced that the company has been selected to present at the 2<sup>nd</sup> Annual Neuroscience BioPartnering and Investment Forum on March 27, 2017. The company's CEO, Dr. Gergely Tóth, will give a presentation at 10:45 in Presentation Track A, at the New York Academy of Sciences, 250 Greenwich St, New York.

The company will be presenting information and results from its small molecule pharmacological chaperone programs targeting the Tau protein for Alzheimer's and the DJ-1 protein for Parkinson's, and details of the company's therapeutic approach of tackling the diseases at their source; preventing protein aggregation and the harmful effects of oxidative stress.

### ***About Cantabio Pharmaceuticals, Inc.***

Cantabio is focused on bringing novel, first-in-class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics. These programs are aimed at tackling the root causes of key neurodegenerative disorders, including Alzheimer's and Parkinson's disease, by preventing the aggregation of key protein targets and protecting against oxidative stress. The company is currently engaged in advanced pre-clinical trials of its therapeutic candidates and is focused on developing these towards clinical trials. More information is available at [www.cantabio.com](http://www.cantabio.com).

### ***About the 2<sup>nd</sup> Annual Neuroscience BioPartnering and Investment Forum.***

Event will focus on key areas of neurodegenerative diseases and pain management with a mix of specialist panels and company presentations. The event is targeted at buy and sell side analysts from investment banks and funds and partnering executives from pharma. <http://www.sachsforum.com/2nbpi-about.html>

### ***Forward-Looking Statements:***

This press release may contain "forward-looking statements" within the meaning of Section

27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Company contact:

Thomas Sawyer, Ph.D., M.B.A.

COO

Cantabio Pharmaceuticals, Inc.

844-200-CTBO

[ir@cantabio.com](mailto:ir@cantabio.com)

Investors and Media Relations:

[ir@cantabio.com](mailto:ir@cantabio.com)

844-200-CTBO

Source: Cantabio Pharmaceuticals Inc.